Intelligence · Clinical Development
Pipeline search results
Programs matching “paclitaxel” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 72 pipeline programs matching "paclitaxel" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
cadonilimab combined +paclitaxel (albumin-bound)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Adenocarcinoma
1 trial -
nab-paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
nanoparticle albumin-bound paclitaxel/carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
paclitaxel/carboplatin/lapatinib
Hospital Authority, Hong Kong
ErbB2-Positive Stage I-III Breast Cancer
1 trial -
AZD2014 3 on/4 off & weekly paclitaxel
United Therapeutics Europe Ltd
Advanced Cancer
1 trial -
Custirsen, paclitaxel and carboplatin
Teva Pharma GmbH
Cancer
1 trial -
Fostamatinib 100 mg bid and Paclitaxel
RIGEL PHARMACEUTICALS INC
Ovarian Cancer
1 trial -
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
RIGEL PHARMACEUTICALS INC
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
OMP-54F28, Nab-Paclitaxel and Gemcitabine
Mereo BioPharma Group plc
Pancreatic Cancer
1 trial -
OMP-54F28, Paclitaxel and Carboplatin
Mereo BioPharma Group plc
Ovarian Cancer
1 trial -
Paclitaxel
Jazz Pharmaceuticals Ireland Limited
Ovarian Cancer
1 trial -
Paclitaxel
Hospital Authority, Hong Kong
Ovarian Cancer
1 trial -
SKSD00702
BRIGHT MINDS BIOSCIENCES INC.
Advanced Solid Tumors
1 trial -
Vantictumab combined with paclitaxel
Mereo BioPharma Group plc
Metastatic Breast Cancer
1 trial -
paclitaxel cationic liposome for injection
CSPC Baike (Shandong) Biopharmaceutical Co.,
Colorectal Liver Metastases
1 trial -
Tislelizumab + cisplatin + paclitaxel
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Albumin paclitaxel/neutrophil drug
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Albumin-Bound Paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Carcinoma
1 trial -
HY-PA023-001
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Nab-paclitaxel
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Paclitaxel Oral Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small-Cell Lung Cancer
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
The First People's Hospital of Lianyungang
Breast Cancers
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancers
1 trial -
UW 22-704
The University of Hong Kong
Recurrent Ovarian Carcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.